Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Innovation in clinical trials: WINTHER trial

WIN 2019 Symposium

23 - 24 Jun 2019

Published: 10 Jul 2019

Views: 1344

Rating:

Save

Prof Razelle Kurzrock - University of California San Diego, San Diego, USA

Prof Razelle Kurzrock speaks to ecancer at the WIN 2019 Symposium in Paris about the WINTHER trial, which incorporates genomics and transcriptomics to match patients with the most effective drugs.

She summarises the main findings achieved from the trial so far, which include the significance of the RNA data collected in both normal and tumour tissue and the ambiguity that exists when matching patients to the most appropriate drug.

Prof Kurzrock also mentions additional studies that stood out to her from the conference.

Related Videos

The aims of the African Oncogenetics Network

Dr Yosr Hamdi - Pasteur Institute of Tunis, Tunis, Tunisia

The aims of the African Oncogenetics Network ( Dr Yosr Hamdi - Pasteur Institute of Tunis, Tunis, Tunisia )

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer

Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer ( Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA )

Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET/CT and whole-body diffusion weighted MRI

Dr Elena Zamagni - University of Bologna, Bologna, Italy

Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET/CT and whole-body diffusion weighted MRI ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

More from ecancer